INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.90
+0.31 (+3.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.59
Open8.79
Bid0.00 x 800
Ask18.76 x 900
Day's Range8.69 - 9.04
52 Week Range4.10 - 14.00
Volume298,193
Avg. Volume818,845
Market Cap660.78M
Beta (3Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-3.58
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.60
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that its collaboration with the Center for Medicinal Cannabis Research (CMCR) at the University of California (UC) San Diego School of Medicine has added a third study. This additional study will evaluate the pharmacological effects of cannabidiol (CBD) oral solution from INSYS on anxiety associated with anorexia nervosa in adult patients.

  • Meet the Portland attorney defending opioid maker Insys against hundreds of lawsuits
    American City Business Journals4 days ago

    Meet the Portland attorney defending opioid maker Insys against hundreds of lawsuits

    Matt Donohue of Holland & Knight represents Insys Therapeutics but also sits on two committees appointed by the judge presiding over hundreds of lawsuits

  • GlobeNewswire5 days ago

    INSYS Therapeutics Names New General Counsel

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the addition of Mark Nance to its senior management team as chief legal officer and general counsel. “As we continue to transform the company and advance the pipeline strategically and with agility, Mark’s addition will be critical to our executive leadership team,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

  • Insys Therapeutics: Performance and Estimates for Q3
    Market Realist7 days ago

    Insys Therapeutics: Performance and Estimates for Q3

    Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.

  • Insys Therapeutics: Recommendations and Market Capitalization
    Market Realist10 days ago

    Insys Therapeutics: Recommendations and Market Capitalization

    Insys Therapeutics’ (INSY) product pipeline includes cannabidiol oral solution and dronabinol inhalation. It also includes naloxone and epinephrine nasal sprays, buprenorphine and naloxone spray, and buprenorphine sublingual spray.

  • Marijuana-Focused Biotech Companies in Q3: Are They Performing?
    Market Realist10 days ago

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.

  • InvestorPlace14 days ago

    2 Marijuana Biotechs to Watch

    On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.

  • GlobeNewswire14 days ago

    INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has signed a definitive license agreement with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in eight countries in the Middle East. Today’s announcement confirms that the definitive agreement has been executed, making Dubai-based Lunatus the exclusive licensee and authorized agent for SUBSYS in the territory, which comprises Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates. Under the terms of this 10-year agreement, INSYS will supply SUBSYS to Lunatus, and Lunatus will obtain the regulatory approvals and commercialize SUBSYS in the territory.

  • ACCESSWIRE17 days ago

    Stem Cell Companies Moving The Markets

    HENDERSON, NV / ACCESSWIRE / September 28, 2018 / One stem cell play we like a lot is BioRestorative Therapies, Inc., (BRTX) a life sciences company focused on stem cell-based therapies. They recently ...

  • GlobeNewswire17 days ago

    INSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference

    PHOENIX, Sept. 27, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...

  • GlobeNewswire21 days ago

    INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated Inhaler

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently completed a human proof-of-concept study of dronabinol inhalation using a novel and patented breath-actuated device licensed exclusively from U.K.-based Senzer Ltd. “This pharmacokinetic study provides evidence of our unique drug-device combination’s viability as a mechanism to deliver dronabinol into the distal lung for rapid systemic absorption,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics.

  • Motley Fool22 days ago

    Better Buy: Insys Therapeutics, Inc. vs. GW Pharmaceuticals PLC

    Which stock wins in a battle between these two cannabis-focused biotechs?

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...

  • ACCESSWIRE27 days ago

    Cannabis and Biotech Stocks That Could Skyrocket

    HENDERSON, NV / ACCESSWIRE / September 18, 2018 / A very interesting biotech firm DCTH (Delcath Systems, Inc.), has an intriguing treatment for liver cancer. The company has initiated a global Phase 3 ...

  • GlobeNewswirelast month

    INSYS Therapeutics to Present at Janney Healthcare Conference

    PHOENIX, Sept. 14, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...

  • ACCESSWIRElast month

    Intriguing Cannabis and Biotech Firms

    HENDERSON, NV/ ACCESSWIRE / September 14, 2018 / A fascinating biotech firm DCTH (Delcath Systems, Inc.), has a very intriguing treatment for liver cancer. The company has initiated a global Phase 3 clinical ...

  • Could INSYS Therapeutics Inc’s (NASDAQ:INSY) Investor Composition Impacts Your Returns?
    Simply Wall St.last month

    Could INSYS Therapeutics Inc’s (NASDAQ:INSY) Investor Composition Impacts Your Returns?

    Every investor in INSYS Therapeutics Inc (NASDAQ:INSY) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders oftenRead More...

  • Associated Presslast month

    Maryland charges opioid maker with major misconduct

    Maryland authorities announced charges Thursday against an Arizona-based drugmaker that they say engaged in a nationwide scheme "characterized by extraordinary misconduct" to boost profits amid the coast-to-coast opioid epidemic. The office of Attorney General Brian Frosh filed charges against Insys Therapeutics alleging multiple violations of the state's consumer protection law. The pharmaceutical company makes a highly addictive opioid spray used to manage uncontrollable pain for adult cancer patients, but Frosh says Insys joined with local health care providers in a "calculated scheme" to target non-cancer patients, including those seeking relief from knee or back pain.

  • Reuterslast month

    Maryland charges Insys with engaging in deceptive opioid scheme

    Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients. Maryland Attorney General Brian Frosh announced that he had filed administrative charges against Arizona-based Insys, which he said provided thousands of dollars in inducements to doctors to promote prescribing its medication Subsys to their patients. Maryland alleged the company influenced doctors to prescribe the drug beyond its labeled use with inducements that included payments purported to be compensation for participating in educational events.

  • Here's Why INSYS Therapeutics, Inc. Jumped a Whopping 40.3% in August
    Motley Foollast month

    Here's Why INSYS Therapeutics, Inc. Jumped a Whopping 40.3% in August

    A settlement with the U.S. Department of Justice started August off on a good foot, but the month was capped off with a short squeeze.

  • ACCESSWIRElast month

    Cannabis and Biotech Firms Set to Explode

    HENDERSON,NV / ACCESSWIRE / September 4, 2018 / We have discovered an incredibly unique stem cell firm, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the ...

  • Are Options Traders Betting on a Big Move in INSYS Therapeutics (INSY) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in INSYS Therapeutics (INSY) Stock?

    Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that its clinical development collaboration with the Center for Medicinal Cannabis Research (CMCR) at UC San Diego School of Medicine has expanded to include plans for a new study to explore the effectiveness of the company’s proprietary cannabidiol (CBD) oral solution on symptoms, neurocognition, neuroimmune response and eating behavior in patients with early psychosis. The two organizations announced their collaboration in April with plans for a CMCR study of CBD from INSYS in pediatric patients with autism.

  • Here's Why INSYS Therapeutics Inc. Is on a Rollercoaster: Up 34% Yesterday, Down 12% Today
    Motley Foollast month

    Here's Why INSYS Therapeutics Inc. Is on a Rollercoaster: Up 34% Yesterday, Down 12% Today

    The FDA's Fast Track designation isn't all it's cracked up to be.